Matinas BioPharma revenue MTNB

Sales by quarter and over the last twelve months, from 2014.

Matinas BioPharma's revenue was $1.1M over the twelve months to Dec 31, 2023.

In its latest quarter, Q4 FY23, it was $0, down 100% on the same quarter a year before.

Over the five fiscal years to FY2023 it grew 56% a year on average.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q4 FY23	Dec 31, 2023	$0	−100%	$1.1M
Q3 FY23	Sep 30, 2023	$0	−100%	$2.2M
Q2 FY23	Jun 30, 2023	$0	−100%	$3.2M
Q1 FY23	Mar 31, 2023	$1.1M	n/a	$4.3M
Q4 FY22	Dec 31, 2022	$1.1M	n/a	n/a
Q3 FY22	Sep 30, 2022	$1.1M	n/a	n/a
Q2 FY22	Jun 30, 2022	$1.1M	n/a	n/a
Q4 FY21	Dec 31, 2021	$0	−100%	$33.3K
Q3 FY21	Sep 30, 2021	$0	−100%	$95.8K
Q2 FY21	Jun 30, 2021	$0	n/a	$191.7K
Q1 FY21	Mar 31, 2021	$33.3K	n/a	n/a
Q4 FY20	Dec 31, 2020	$62.5K	n/a	n/a

Companies in Healthcare nearest Matinas BioPharma's size, closest first, today.

Company	Revenue, 12 months	Growth
MTNBMatinas BioPharma	n/m
OXBROXBRIDGE RE HOLDINGS	$2.8M	+40% a year
EDUCEducational Development	$20M	−32% a year
GTIMGood Times Restaurants	$135.1M	−6% a year
MDRRMedalist Diversified	$9.6M	−1% a year
Peer median	$14.8M

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.